Faculty

Faculty

Claire Harrison

Professor

Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Professor of Myeloproliferative Neoplasms

Moderator

Neil Love

MD

Research To Practice

Miami, Florida

Additional faculty to be announced.

Tuesday, June 2, 2026
7:00 AM – 8:00 AM central time (8:00 AM – 9:00 AM eastern time)
Live CME/MOC-accredited webinar

A detailed agenda will be made available in the coming weeks.

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of myelofibrosis.

Learning Objectives
To be announced.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY
To be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from GSK and Karyopharm Therapeutics.

Faculty

Faculty

Manish A Shah

MD

Weill Cornell Medicine NewYork-Presbyterian Hospital, New York, New York

Professor of Medicine, Bartlett Family Professor of Gastrointestinal Oncology, Chief, Solid Tumor Oncology

Faculty

Eric Van Cutsem

MD, PhD

University Hospitals Leuven, Leuven, Belgium

Professor of Medicine, Digestive Oncology

Moderator

Yelena Y Janjigian

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Professor and Chief Attending, Gastrointestinal Oncology Service

Program Schedule — Central Time
11:15 AM – 11:30 AM — Registration
11:30 AM – 1:00 PM — Educational Lunch Meeting

MODULE 1: Targeting CLDN18.2 in Advanced Gastroesophageal Cancers

• Incidence and clinical relevance of CLDN18.2 expression in gastric and gastroesophageal junction (GEJ) cancer; appropriate methods to assess CLDN18.2 status
• Key efficacy and safety results from the Phase III SPOTLIGHT and GLOW trials evaluating zolbetuximab in combination with chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric/GEJ adenocarcinoma
• FDA approval and current clinical role of up-front zolbetuximab/chemotherapy
• Spectrum, frequency and severity of adverse events associated with zolbetuximab; optimal approaches to prevention and management
• Recently presented results with zolbetuximab in combination with modified FOLFOX6 and nivolumab for patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma in the Phase II ILUSTRO trial; implications for current and future practice
• Design, eligibility criteria and key efficacy and safety endpoints of the Phase III LUCERNA trial evaluating zolbetuximab in combination with pembrolizumab and chemotherapy as first-line treatment for CLDN18.2-positive, HER2-negative, PD-L1-positive gastric/GEJ cancer
• Structural components of the CLDN18.2-targeted antibody-drug conjugate sonesitatug vedotin and early efficacy and safety results with this therapy for advanced gastroesophageal cancers

MODULE 2: HER2-Targeted Approaches for Advanced Gastroesophageal Cancers

• Available efficacy and safety findings with and current clinical role of trastuzumab/pembrolizumab/chemotherapy for patients with untreated HER2-positive advanced gastric/GEJ adenocarcinoma
• Mechanism of action of the novel HER2-targeted bispecific antibody zanidatamab
• Early research findings with zanidatamab/chemotherapy as first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma
• Design, eligibility criteria and key efficacy and safety endpoints from the Phase III HERIZON-GEA-01 trial evaluating zanidatamab/chemotherapy with or without tislelizumab as first-line treatment for gastroesophageal adenocarcinoma
• Recently presented results from the HERIZON-GEA-01 trial demonstrating a progression-free survival (PFS) and overall survival advantage with zanidatamab/chemotherapy/tislelizumab and a PFS benefit with zanidatamab/chemotherapy; implications for current and future disease management
• Spectrum, frequency and optimal approaches to the management of toxicities associated with zanidatamab
• Published efficacy and safety data from the Phase III DESTINY-Gastric04 trial comparing trastuzumab deruxtecan (T-DXd) to ramucirumab/paclitaxel for patients with HER2-positive metastatic gastric cancer or GEJ adenocarcinoma who had previously received trastuzumab-based therapy
• Optimal integration of T-DXd into the current management of advanced HER2-positive gastroesophageal tumors

MODULE 3: Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers

• Clinical and biological factors in the choice of up-front therapy for patients with metastatic gastroesophageal cancers
• Published datasets demonstrating the efficacy and safety of first-line nivolumab-, pembrolizumab- and tislelizumab-containing regimens for advanced HER2-negative gastric, GEJ and esophageal cancers; impact of PD-L1 expression on outcomes
• Recent narrowing of the FDA-approved indications for nivolumab- and pembrolizumab-containing regimens for previously untreated HER2-negative gastroesophageal cancers
• Clinical utility, if any, of immunotherapy for relapsed/refractory gastroesophageal tumors
• Optimal approaches to the prevention and management of toxicities observed with immune checkpoint inhibitors

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess available data with monoclonal antibody therapy directed at claudin 18.2 (CLDN18.2) in combination with chemotherapy as first-line treatment for patients with HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction (GEJ) cancer, and optimally incorporate this approach into management algorithms.
• Review published research findings with HER2-targeted therapies for patients with HER2-positive gastroesophageal cancers, and assess the current nonresearch role of various agents and regimens.
• Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of metastatic gastric, GEJ and esophageal cancer, and optimally integrate these strategies into treatment algorithms.
• Recognize the spectrum, frequency and severity of toxicities associated with agents and regimens with established activity in advanced gastroesophageal cancers in order to facilitate the safe and effective use of these therapies.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Shah has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Prof Van Cutsem — Consulting Agreements: AbbVie Inc, Agenus Inc, ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cantargia, Daiichi Sankyo Inc, Debiopharm, Eisai Inc, ElmediX, Fosun Pharma, Galapagos NV, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Merck KGaA, Microbial Machines, Mirati Therapeutics Inc, MSD, Nordic Pharma, Novartis, Novocure Inc, Pfizer Inc, Pierre Fabre, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Simcere, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Trishula Therapeutics, Zymeworks Inc. 

MODERATOR
Dr Janjigian — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc; Consulting Agreements: AbbVie Inc, AlphaSights, Arcus Biosciences, ARS Pharmaceuticals, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cencora, Daiichi Sankyo Inc, Eisai Inc, Geneos Therapeutics, Gilead Sciences Inc, GSK, Guardant Health, HC Wainwright & Co, Health Advances, Imugene, Inspirna, Lilly, Lynx Health, Merck, Merck Serono, Mersana Therapeutics Inc, PeerMD, Pfizer Inc, Sanofi, Seagen Inc, Suzhou Liangyihui Network Technology Co Ltd, Zymeworks Inc; Contracted Research: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, Debbie’s Dream Foundation, eChinaHealth, ED Medresources Inc, Fred’s Team, HMP, i3Health, Imedex, Mashup Media LLC, Master Clinician Alliance, MJH Life Sciences, National Cancer Institute, OncoDaily (stock options), Paradigm Medical Communications, PeerView, Physician Education Resource (PER), Stand Up 2 Cancer, Talem Health, TotalCME, US Department of Defense, WebMD.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Jazz Pharmaceuticals Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Tuesday, June 23, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to be announced.

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers.

Learning Objectives
To be announced.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Dr Shitara has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Ilson — Advisory Committees: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Merck, Oncolys BioPharma, Roche Laboratories Inc, Taiho Oncology Inc; Consulting Agreements: Astellas.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeOne, and Daiichi Sankyo Inc.

Tuesday, June 30, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to be announced.

Target Audience
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
To be announced.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
To be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, and Nuvation Bio Inc.

Faculty

Faculty

Christopher Flowers

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Faculty

Matthew Lunning

DO

University of Nebraska Medical Center, Omaha, Nebraska

Professor, Medical Director, Gene and Cellular Therapy, Assistant Vice Chancellor for Clinical Research, Fred and Pamela Buffett Cancer Center

Faculty

Sonali M Smith

MD

The University of Chicago, Chicago, Illinois

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology/Oncology, Co-Leader, Cancer Service Line

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Additional faculty to be announced.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Rational Incorporation of CD79b- Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

• Key factors in the selection of initial therapy for patients with DLBCL
• Extended follow-up from the Phase III POLARIX trial comparing polatuzumab vedotin with rituximab/cyclophosphamide/doxorubicin/prednisone (R-CHP) to R-CHOP for patients with previously untreated DLBCL; clinical activity observed with polatuzumab vedotin/R-CHP in various patient subsets
• Appropriate selection of patients to receive polatuzumab vedotin as a component of up-front therapy for DLBCL
• Efficacy and safety findings from the Phase III POLARGO study of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin for patients with R/R DLBCL; potential role of this regimen
• Available and emerging results, including those from the Phase III SUNMO trial, with polatuzumab vedotin combined with bispecific antibodies for patients with R/R DLBCL

MODULE 2: Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and FL

• Extended follow-up from the Phase II L-MIND study supporting the use of tafasitamab/lenalidomide for patients with R/R DLBCL
• Optimal sequencing of tafasitamab/lenalidomide for individual patients with R/R DLBCL
• Biological rationale for the evaluation of tafasitamab for FL
• Key efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide and rituximab (R2) for R/R FL or marginal zone lymphoma
• FDA approval of tafasitamab/R2 for patients with R/R FL; selection of appropriate candidates for this approach

MODULE 3: Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL

• Extended follow-up from the Phase II LOTIS-2 study supporting the use of loncastuximab tesirine for patients with R/R DLBCL
• Optimal sequencing of loncastuximab tesirine for individual patients with R/R DLBCL and ongoing studies designed to further define its role
• Initial results from the Phase Ib LOTIS-7 study of loncastuximab tesirine in combination with glofitamab for R/R DLBCL; implications for clinical practice and ongoing research
• Available data with loncastuximab tesirine for other subtypes of non-Hodgkin lymphoma (NHL)
• Recent NCCN Guidelines inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 4: Current and Future Role of Bruton Tyrosine Kinase (BTK) Inhibition in Therapy for NHL

• Key efficacy and safety outcomes with the addition of acalabrutinib to bendamustine/rituximab (BR) and maintenance rituximab for patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for transplant
• Recent FDA approval of acalabrutinib/BR as a front-line regimen for MCL; identification of optimal candidates for this strategy
• Published research findings with and ongoing studies of covalent BTK inhibitors as a component of up-front chemotherapy-free combination regimens for MCL
• Published efficacy and safety data from the Phase II ROSEWOOD study of zanubrutinib in combination with obinutuzumab for patients with FL who had received 2 or more previous systemic therapies
• FDA approval of zanubrutinib/obinutuzumab for R/R FL; current clinical role and ongoing Phase III evaluation
• Published clinical trial experience with BTK inhibitors for patients with newly diagnosed DLBCL
• Design, eligibility criteria and primary and secondary endpoints of the Phase III ESCALADE trial of acalabrutinib in combination with R-CHOP for patients aged 65 or younger with untreated non-GCB DLBCL; estimated completion date

MODULE 5: Potential Role of Bcl-2 Inhibitors in Therapy for MCL

• Available data with and current clinical role of venetoclax as monotherapy or in combination with rituximab or a BTK inhibitor for patients with R/R MCL
• Mechanistic similarities and differences between venetoclax and the next-generation Bcl-2 inhibitor sonrotoclax; implications for efficacy and tolerability
• Emerging positive findings from the BGB-11417-201 trial evaluating sonrotoclax monotherapy for R/R MCL
• FDA breakthrough therapy designation for sonrotoclax for R/R MCL and potential clinical role
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CELESTIAL-RRMCL study comparing sonrotoclax and zanubrutinib to placebo and zanubrutinib for patients with R/R MCL; estimated completion date

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy would be appropriate.
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and apply this information in patient education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with relapsed/refractory (R/R) DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for patients with mantle cell lymphoma (MCL), FL and DLBCL, and determine the role of these agents in current and future clinical management.
• Assess emerging research findings with Bcl-2 inhibitors for patients with R/R MCL in order to prepare for the potential clinical availability of this novel treatment strategy.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Incyte Corporation.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Faculty

Faculty

Paul G Richardson

MD

Dana-Farber Cancer Institute, Boston, Massachusetts

Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center

Harvard Medical School, Boston, Massachusetts

RJ Corman Professor of Medicine

Moderator

Sagar Lonial

MD, FACP, FASCO

Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Chair and Professor, Department of Hematology and Medical Oncology, Chief Medical Officer

Additional faculty to be announced.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in patients with R/R MM
• Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; overall survival findings from CARTITUDE-4
• FDA approvals of ide-cel and cilta-cel in earlier settings; identification of patients appropriate for CAR T-cell therapy and optimal sequencing with regard to other evidence-based approaches
• Spectrum, incidence and severity of acute and long-term toxicities with BCMA-directed CAR T-cell therapy in patients with MM; appropriate monitoring and management algorithms
• Rationale for the evaluation of CAR T-cell platforms with novel targets and/or manufacturing processes for R/R MM
• Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA regenerative medicine advanced therapy designation and ongoing evaluation
• Preliminary efficacy and safety results from the Phase Ib/II DURGA-1 study of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy using the FasTCAR rapid manufacturing platform, for R/R MM; future development plans
• Preliminary data and ongoing clinical research with other novel CAR T-cell platforms for R/R MM

MODULE 2: Integrating Bispecific Antibodies into the Management of R/R MM

• Similarities and differences in the cellular targets and mechanisms of action of the various bispecific antibodies used for MM
• Efficacy and safety findings leading to the FDA approvals of the BCMA-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab for heavily pretreated MM; optimal incorporation into current management algorithms
• Published and emerging Phase III findings with teclistamab, either in combination (from the MajesTEC-3 trial) or as monotherapy (from the MajesTEC-9 trial), in earlier lines of treatment; clinical implications
• Key efficacy and safety data with the GPRC5D-targeted bispecific antibody talquetamab for heavily pretreated disease; optimal selection of patients for this agent
• Biological rationale for and published findings with the FcRH5-directed bispecific antibody cevostamab in the treatment of R/R MM
• Optimal selection of patients with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other
• Rationale for, early data with and ongoing studies — including in the first-line setting — of bispecific antibodies in combination with other bispecific antibody platforms or standard systemic therapies for MM
• Incidence and severity of cytokine release syndrome, neurotoxicity and other adverse events (AEs) with BCMA- and non-BCMA-targeted bispecific antibodies; optimal mitigation and management strategies
• Ongoing and planned Phase III research studies with bispecific antibodies alone and in combination for MM

MODULE 3: Potential Utility of Antibody-Drug Conjugates for MM

• Mechanism of action and structural components of belantamab mafodotin
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM
• Key efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and with pomalidomide/dexamethasone, respectively, for patients who have received ≥1 prior line of therapy; overall survival findings from DREAMM-7
• FDA approval and current role of belantamab mafodotin-based combination strategies in the management of R/R MM
• Incidence, severity, mitigation and management of belantamab mafodotin-related adverse events (AEs), including ocular toxicities

MODULE 4: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) in Therapy for MM

• Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs (IMiDs)
• Available data documenting the efficacy and safety of iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for patients with R/R MM
• Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone compared to daratumumab/bortezomib/dexamethasone for patients with R/R MM
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs
• Spectrum, frequency and severity of AEs observed with CELMoDs in published clinical studies; comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory (R/R) multiple myeloma (MM).
• Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered and/or recommended.
• Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
• Recall presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
• Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators to prepare for the potential clinical availability of these agents for patients with R/R MM.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly used in the care of patients with R/R MM.
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and as applicable, discuss clinical trial participation with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Faculty

Faculty

Andrea Cercek

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Section Head, Colorectal Cancer, Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers, Attending, Gastrointestinal Oncology Service, Department of Medicine

Faculty

Arvind Dasari

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Gastrointestinal Medical Oncology

Moderator

Tanios Bekaii-Saab

MD

Mayo Clinic Comprehensive Cancer Center (All Sites)

David F and Margaret T Grohne Professor of Novel Therapeutics for Cancer Research I, Chair and Consultant, Division of Hematology and Medical Oncology, Co-Leader, Advanced Clinical and Translational Science Program

Mayo Clinic in Arizona, Phoenix, Arizona

Professor, Mayo Clinic College of Medicine and Science

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:00 PM — Educational Meeting

MODULE 1: Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Localized and Locally Advanced Colorectal Cancer (CRC)

• Current role of neoadjuvant and adjuvant systemic treatment in localized/locally advanced rectal and colon tumors; historical outcomes achieved with chemotherapy and chemoradiation therapy for patients with MSI-H/dMMR disease
• Updated results with dostarlimab as an alternative to surgery for MSI-H/dMMR locally advanced rectal cancer; implications for organ preservation
• FDA breakthrough therapy designation for dostarlimab for patients with locally advanced MSI-H/dMMR rectal cancer; ongoing evaluation in the registrational Phase II AZUR-1 trial
• Early-phase data with neoadjuvant anti-PD-1/PD-L1 antibodies alone or in combination with other immunotherapies for patients with nonmetastatic MSI-H/dMMR colon cancer; ongoing Phase III AZUR-2 study of perioperative dostarlimab in this population
• Design, eligibility criteria and key efficacy and safety findings from the Phase III Alliance A021502/ATOMIC trial assessing atezolizumab in combination with mFOLFOX6 and continued as monotherapy in the adjuvant setting for patients with Stage III CRC and dMMR tumors
• Patient selection for and potential role of adjuvant atezolizumab for patients with Stage III CRC

MODULE 2: Clinical Relevance and Practical Use of Molecular Residual Disease (MRD) Analysis in CRC

• Biological rationale for circulating tumor DNA (ctDNA)-based MRD monitoring in CRC; benefits of ctDNA monitoring over traditional means of follow-up
• Published datasets (eg, the CIRCULATE-Japan and BESPOKE CRC trials) evaluating the use of ctDNA testing to identify patients at increased risk of recurrence
• Recent findings from various studies (eg, the DYNAMIC, CALGB/SWOG-80702, ALTAIR and ALASCCA trials) attempting to validate the use of ctDNA testing in predicting benefit from adjuvant treatment regimens
• Ongoing Phase III trials examining the clinical utility of ctDNA-based MRD testing for guiding treatment decision-making in localized CRC
• Available evidence supporting the use of ctDNA as a tool for monitoring for recurrence after curative-intent therapy; recommended timing and frequency of ctDNA testing in the surveillance setting
• Current and potential future role of ctDNA testing in localized, locally advanced and metastatic CRC

MODULE 3: Recent Advances in Metastatic CRC (mCRC) — Optimizing Immunotherapy and Other Approaches

• Rationale for the evaluation of dual immune checkpoint inhibition for newly diagnosed mCRC
• Design, eligibility criteria and key endpoints of the Phase III CheckMate 8HW trial assessing nivolumab/ipilimumab versus chemotherapy with or without bevacizumab or cetuximab for previously untreated MSI-H/dMMR mCRC
• Key efficacy and safety findings from the CheckMate 8HW trial assessing nivolumab/ipilimumab versus chemotherapy with or without bevacizumab or cetuximab for previously untreated MSI-H/dMMR mCRC; FDA approval and current role of nivolumab/ipilimumab in first-line therapy
• Biological rationale for dual targeting of EGFR and MET with amivantamab for patients with mCRC
• Available efficacy and safety findings from the Phase Ib/II OrigAMI-1 trial evaluating amivantamab as monotherapy and in combination with chemotherapy for patients with mCRC
• Design, eligibility criteria and primary and secondary endpoints of the Phase III OrigAMI-2 and OrigAMI-3 trials evaluating subcutaneous amivantamab with FOLFOX and FOLFIRI; potential clinical role of amivantamab in therapy for patients with mCRC
• Available data with immune checkpoint inhibitors alone and in combination with other agents for patients with microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) mCRC
• Mechanistic similarities and differences between zanzalintinib and other multikinase inhibitors for CRC; rationale for combining zanzalintinib with an anti-PD-1/PD-L1 antibody in therapy for mCRC
• Recently presented efficacy and safety findings from the Phase III STELLAR-303 trial evaluating zanzalintinib with atezolizumab for pretreated MSS/pMMR mCRC; implications for therapeutic sequencing
• Future development plans for zanzalintinib/atezolizumab in the management of CRC and implications for therapeutic sequencing
• Available data with and optimal use of targeted therapy for patients with mCRC and a BRAF, HER2 or KRAS G12C mutation

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand validated biomarkers of response (eg, RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression, BRAF V600E mutations, KRAS G12C mutations) found in patients with CRC, and consider the implications for molecular testing and clinical care.
• Evaluate the biological rationale for the use of immune checkpoint inhibitors in the management of MSI-high (MSI-H)/mismatch repair-deficient (dMMR) localized and advanced CRC, and counsel patients regarding evidence-based and guideline-endorsed treatment recommendations.
• Optimize the current and future use of neoadjuvant and adjuvant therapy for patients with localized and locally advanced CRC, considering the influence of various clinical and biological factors such as MSI-H/dMMR status.
• Recognize the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in CRC, and comprehend the rationale for its use in detecting molecular residual disease.
• Appreciate published datasets documenting the clinical utility of ctDNA testing in risk stratification, surveillance and treatment decision-making for patients with CRC, and consider the current and future role of this strategy in personalizing therapeutic recommendations.
• Formulate a plan to guide the selection and sequencing of therapies for patients diagnosed with metastatic CRC (mCRC) accounting for tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
• Appreciate published research documenting the efficacy of targeted therapeutic approaches for patients with mCRC and various actionable genomic alterations in order to personalize treatment recommendations.
• Recall ongoing trials evaluating novel agents and strategies for patients with mCRC, and use this information to refer candidates for study participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Cercek — Advisory Boards: 3T Biosciences, AbbVie Inc, Agents, Amgen Inc, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Summit Therapeutics, UroGen Pharma; Contracted Research: GSK, Pfizer Inc. Dr Dasari — Advisory Committees: Agenus Inc, Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Crinetics Pharmaceuticals, Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, RayzeBio, Taiho Oncology Inc, Xencor.

MODERATOR
Dr Bekaii-Saab — Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KGaA, Merus, Pfizer Inc, Revolution Medicines, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeOne, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Lisata Therapeutics, Natera Inc, Sanofi, Sobi, Stemline Therapeutics Inc, Takeda Pharmaceuticals USA Inc, Treos Bio, Xilio Therapeutics, Zai Lab; Data and Safety Monitoring Boards/Committees: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): Agios Pharmaceuticals Inc, AltruBio, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Seagen Inc, Sumitomo Pharma America; Scientific Advisory Boards: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Panbela Therapeutics Inc, Replimune, Xilis; Nonrelevant Financial Relationships: MJH Life Sciences, Pancreatic Cancer Action Network, The Valley Hospital.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Exelixis Inc, GSK, and Natera Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.